Molsidomin Retard Heumann (Molsidomine)

Molsidomine is a prodrug that releases nitric oxide after metabolism. The nitric oxide relaxes vascular smooth muscle through the cyclic GMP pathway, causing coronary vasodilation and reducing myocardial oxygen demand.

The appropriate dose of molsidomine is determined by the prescribing physician based on the patient’s clinical condition, response, and any co‑existing medical issues.

Safety data for molsidomine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under medical supervision.

Submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Molsidomine belongs to the nitric oxide donor class, offering vasodilation without the rapid tolerance seen with nitrates. Compared with beta‑blockers or calcium‑channel blockers, it primarily improves coronary blood flow rather than reducing heart rate or contractility.

Store the product at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight and excessive heat to maintain stability.

The medication is taken orally, usually with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water.

Serious risks include severe hypotension, syncope, allergic reactions such as angioedema, and rare cases of myocardial infarction. Patients should seek immediate medical attention if they experience sudden dizziness, fainting, or signs of an allergic reaction.

Molsidomine should be avoided in patients with known hypersensitivity to the drug, those taking other nitric oxide donors, and individuals with severe hypotension or uncontrolled heart failure unless specifically advised by a physician.